X4 Pharmaceuticals, Inc. (XFOR)
4.04
-0.03
(-0.74%)
USD |
NASDAQ |
Sep 02, 16:00
4.01
-0.03
(-0.74%)
Pre-Market: 08:11
X4 Pharmaceuticals Research and Development Expense (TTM) : 66.27M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 66.27M |
| March 31, 2026 | 69.41M |
| December 31, 2025 | 72.22M |
| September 30, 2025 | 75.34M |
| June 30, 2025 | 77.12M |
| March 31, 2025 | 79.65M |
| December 31, 2024 | 81.22M |
| September 30, 2024 | 74.82M |
| June 30, 2024 | 74.30M |
| March 31, 2024 | 68.67M |
| December 31, 2023 | 70.42M |
| September 30, 2023 | 73.73M |
| June 30, 2023 | 68.76M |
| March 31, 2023 | 67.00M |
| December 31, 2022 | 59.06M |
| September 30, 2022 | 52.22M |
| June 30, 2022 | 51.30M |
| March 31, 2022 | 50.68M |
| December 31, 2021 | 48.76M |
| September 30, 2021 | 48.99M |
| Date | Value |
|---|---|
| June 30, 2021 | 47.26M |
| March 31, 2021 | 43.67M |
| December 31, 2020 | 40.90M |
| September 30, 2020 | 36.06M |
| June 30, 2020 | 33.68M |
| March 31, 2020 | 33.42M |
| December 31, 2019 | 30.16M |
| September 30, 2019 | 27.79M |
| June 30, 2019 | 25.36M |
| March 31, 2019 | 21.26M |
| December 31, 2018 | 20.35M |
| September 30, 2018 | 24.89M |
| June 30, 2018 | 29.33M |
| March 31, 2018 | 28.48M |
| December 31, 2017 | 28.13M |
| September 30, 2017 | 23.12M |
| June 30, 2017 | 19.96M |
| March 31, 2017 | 19.69M |
| December 31, 2016 | 17.83M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Sarepta Therapeutics, Inc. | 783.60M |
| Arrowhead Pharmaceuticals, Inc. | 699.56M |
| Oncolytics Biotech, Inc. | 13.11M |
| Sangamo Therapeutics, Inc. | 113.79M |
| Anixa Biosciences, Inc. | 4.557M |